FilingSEC EDGAR8-K
Aytu BioPharma Announces Fiscal 2026 Fourth Quarter and Full Year Results
· SEC accepted
StageEarnings Release
Filing content
The company reported fourth quarter net revenue of $16.1 million, a 6.4% increase year-over-year, while full year net revenue decreased 13.3% to $57.6 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…